Rocket Pharmaceuticals Inc(RCKT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.18 | Insider Own | 5.57% | Shs Outstand | 109.5M | Perf Week | 1.79% |
| Market Cap | 0.25B | Forward P/E | - | EPS next Y | -948.43% | Insider Trans | -3.32% | Shs Float | 103.7M | Perf Month | -12.14% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | -0.4 | Inst Own | 91.67% | Short Float | 14.52% | Perf Quarter | -27.39% |
| Income | -0.02B | P/S | - | EPS this Y | 93.53% | Inst Trans | 1.2% | Short Ratio | 8.35 | Perf Half Y | -34.67% |
| Sales | 0.00B | P/B | 0.68 | EPS next 5Y | 18.58% | ROA | -4.09% | Short Interest | 15.05M | Perf YTD | -35.04% |
| Book/sh | 3.37 | P/C | 0.88 | EPS past 3/5Y | 14.88% 4.46% | ROE | -4.77% | 52W High | -58.17% ($5.45) | Perf Year | -40.78% |
| Cash/sh | 2.58 | P/FCF | - | Sales past 3/5Y | - | ROIC | -4.42% | 52W Low | 5.31% ($2.16) | Perf 3Y | -87.38% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 93.45% | Gross Margin | - | Volatility(W/M) | 6.74% 6.84% | Perf 5Y | -92.22% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.18 | Perf 10Y | -92.5% |
| Dividend Ex-Date | - | Quick Ratio | 9.24 | EPS Q/Q | 273.32% | Profit Margin | - | RSI (14) | 37.6 | Recom | 2.14 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.24 | Sales Q/Q | - | SMA20 | -5.74% ($2.42) | Beta | 0.52 | Target Price | $8.58 |
| Payout | - | Debt/Eq | 0.07 | Earnings | 2026/8/10 | SMA50 | -25.03% ($3.04) | Rel Volume | 0.84 | Prev Close | $2.29 |
| Employees | 202 | LT Debt/Eq | 0.06 | EPS/Sales Surpr. | 25.58% -100% | SMA200 | -34.41% ($3.48) | Avg Volume(3M) | 1.80M | Price | $2.28 |
| IPO | 2015/2/18 | Option/Short | Yes/Yes | Trades | 5590 | Volume | 1,514,778 | Change | -0.44% |
A US clinical- and commercial-stage biotech company developing gene therapies for rare genetic diseases. It operates two platforms — one based on hematopoietic stem cells (lentiviral) and another based on adeno-associated virus (AAV) targeting cardiac diseases — and focuses on areas of high unmet need such as rare immune deficiencies and cardiomyopathies.
Over the past 1 year, on the lower side
58% below its 1-year high.
Traded about as much as usual. That is 84% of its average volume.
RCKT has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +93.5% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -92.2%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 91.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #277 of 594 in the industry
Based on market cap of $250M.
LCTX#273 Lineage Cell Therapeutics Inc $252M PER - 
QTTB#274 Q32 Bio Inc $252M PER 2.8 
GLSI#275 Greenwich LifeSciences Inc $251M PER - 
CUVL#276 Clinuvel Pharmaceuticals Ltd ADR $250M PER 10.8 RCKT#277 Rocket Pharmaceuticals Inc $250M PER - 
FAQ
What kind of company is RCKT?
RCKT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of RCKT?
The market cap of RCKT is approximately $250M, ranking 3,828 within its sector.
What is the 52-week high and low for RCKT?
RCKT has recorded a 52-week high of $5.45 and a low of $2.16.
